Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

This Quarterly Report on Form 10-Q contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Meridian relies on proprietary, patented and licensed technologies, and the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in

unanticipated expenses and delays and interruptions to the sale of new and existing products. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.


	Three Months Ended March 31,						Six Months Ended March 31,						Three Months Ended June 30,						Nine Months Ended June 30,
	2015			2014			2015			2014			2015			2014			2015			2014
NET REVENUES	$	51,545		$	50,134		$	99,558		$	94,928		$	48,204		$	47,212		$	147,762		$	142,140

COST OF SALES		19,024			18,541			37,800			35,328			17,873			17,970			55,673			53,298


GROSS PROFIT		32,521			31,593			61,758			59,600			30,331			29,242			92,089			88,842


OPERATING EXPENSES
Research and development		3,368			3,186			6,471			6,039			3,214			3,146			9,685			9,185
Selling and marketing		6,481			6,461			12,561			12,538			6,184			6,249			18,745			18,787
General and administrative		6,940			6,280			14,325			13,731			6,535			6,715			20,860			20,446

Total operating expenses		16,789			15,927			33,357			32,308			15,933			16,110			49,290			48,418


OPERATING INCOME		15,732			15,666			28,401			27,292			14,398			13,132			42,799			40,424

OTHER INCOME (EXPENSE)
Interest income		6			6			12			10			6			5			18			15
Other, net		(211	)		(28	)		(793	)		(248	)		(99	)		(257	)		(892	)		(505	)

Total other income (expense)		(205	)		(22	)		(781	)		(238	)		(93	)		(252	)		(874	)		(490	)


EARNINGS BEFORE INCOME TAXES		15,527			15,644			27,620			27,054			14,305			12,880			41,925			39,934

INCOME TAX PROVISION		5,457			5,344			9,649			9,328			5,203			4,045			14,852			13,373

NET EARNINGS	$	10,070		$	10,300		$	17,971		$	17,726		$	9,102		$	8,835		$	27,073		$	26,561


BASIC EARNINGS PER COMMON SHARE	$	0.24		$	0.25		$	0.43		$	0.43		$	0.22		$	0.21		$	0.65		$	0.64

DILUTED EARNINGS PER COMMON SHARE	$	0.24		$	0.24		$	0.43		$	0.42		$	0.22		$	0.21		$	0.64		$	0.63

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC		41,707			41,471			41,636			41,434			41,714			41,478			41,647			41,445

EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS		341			676			336			686			379			618			352			669


WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED		42,048			42,147			41,972			42,120			42,093			42,096			41,999			42,114


ANTI-DILUTIVE SECURITIES:
Common share options and restricted shares and units		570			168			546			137			493			337			567			161


DIVIDENDS DECLARED PER COMMON SHARE	$	0.20		$	0.20		$	0.40		$	0.39		$	0.20		$	0.20		$	0.60		$	0.59

The accompanying notes are an integral part of these condensed consolidated financial statements.


	Three Months Ended March 31,					Six Months Ended March 31,					Three Months Ended June 30,				Nine Months Ended June 30,
	2015			2014		2015			2014		2015		2014		2015			2014
NET EARNINGS	$	10,070		$	10,300	$	17,971		$	17,726	$	9,102	$	8,835	$	27,073		$	26,561

Foreign currency translation adjustment		(2,138	)		337		(3,503	)		1,060		1,357		361		(2,146	)		1,421


COMPREHENSIVE INCOME	$	7,932		$	10,637	$	14,468		$	18,786	$	10,459	$	9,196	$	24,927		$	27,982

The accompanying notes are an integral part of these condensed consolidated financial statements.


Six Months Ended March 31,	2015			2014
Nine Months Ended June 30,							2015			2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	17,971		$	17,726		$	27,073		$	26,561
Non-cash items included in net earnings:
Depreciation of property, plant and equipment		1,832			1,756			2,585			2,634
Amortization of intangible assets		900			1,042			1,309			1,549
Amortization of deferredillumigene instrument costs		754			864			1,088			1,281
Stock-based compensation		1,954			2,157			2,676			2,662
Deferred income taxes		(257	)		(31	)		(270	)		(438	)
Loss on disposition and write-down of fixed assets and other assets								39			22
Change in current assets		(6,910	)		(6,656	)		(4,399	)		(6,804	)
Change in current liabilities		3,368			(3,143	)		796			(4,055	)
Other, net		419			(159	)		299			199

Net cash provided by operating activities		20,031			13,556			31,196			23,611


CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment		(2,561	)		(2,573	)		(3,783	)		(3,968	)
Proceeds from sale of assets								1,138			—
Purchases of intangible assets		—			(1,677	)		—			(1,687	)

Net cash used for investing activities		(2,561	)		(4,250	)		(2,645	)		(5,655	)


CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid		(16,671	)		(16,169	)		(25,014	)		(24,464	)
Proceeds and tax benefits from exercises of stock options		654			540			654			629


Net cash used for financing activities		(16,017	)		(15,629	)		(24,360	)		(23,835	)


Effect of Exchange Rate Changes on Cash and Equivalents		(1,781	)		254			(1,263	)		882

Net Decrease in Cash and Equivalents		(328	)		(6,069	)
Net Increase (Decrease) in Cash and Equivalents								2,928			(4,997	)

Cash and Equivalents at Beginning of Period		43,047			44,282			43,047			44,282

Cash and Equivalents at End of Period	$	42,719		$	38,213		$	45,975		$	39,285

The accompanying notes are an integral part of these condensed consolidated financial statements.


	March 31, 2015 (Unaudited)		September 30, 2014		June 30, 2015 (Unaudited)		September 30, 2014
CURRENT ASSETS
Cash and equivalents	$	42,719	$	43,047	$	45,975	$	43,047
Accounts receivable, less allowances of $220 and $272		30,298		23,232
Accounts receivable, less allowances of $256 and $272						27,963		23,232
Inventories		33,043		35,495		33,592		35,495
Prepaid expenses and other current assets		6,483		7,058		6,439		7,058
Deferred income taxes		3,991		3,916		4,006		3,916


Total current assets		116,534		112,748		117,975		112,748


PROPERTY, PLANT AND EQUIPMENT, at Cost
Land		1,150		1,173		984		1,173
Buildings and improvements		29,938		29,146		29,872		29,146
Machinery, equipment and furniture		40,580		40,192		41,761		40,192
Construction in progress		895		652		535		652

Subtotal		72,563		71,163		73,152		71,163
Less: accumulated depreciation and amortization		44,541		43,553		45,771		43,553


Net property, plant and equipment		28,022		27,610		27,381		27,610


OTHER ASSETS
Goodwill		22,090		23,193		22,784		23,193
Other intangible assets, net		6,591		7,813		6,374		7,813
Restricted cash		1,000		1,000		1,000		1,000
Deferredillumigene instrument costs, net		2,270		2,740		2,000		2,740
Deferred income taxes		1,402		1,483		1,398		1,483
Other assets		403		342		404		342


Total other assets		33,756		36,571		33,960		36,571


TOTAL ASSETS	$	178,312	$	176,929	$	179,316	$	176,929

The accompanying notes are an integral part of these condensed consolidated financial statements.


	March 31, 2015 (Unaudited)			September 30, 2014		June 30, 2015 (Unaudited)			September 30, 2014
CURRENT LIABILITIES
Accounts payable	$	6,110		$	4,966	$	5,453		$	4,966
Accrued employee compensation costs		4,899			4,761		4,236			4,761
Other accrued expenses		3,138			3,149		2,630			3,149
Income taxes payable		1,079			859		969			859


Total current liabilities		15,226			13,735		13,288			13,735


NON-CURRENT LIABILITIES		1,988			2,165		2,097			2,165

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY
Preferred stock, no par value, 1,000,000 shares authorized, none issued		—			—		—			—
Common shares, no par value, 71,000,000 shares authorized, 41,713,675 and 41,622,216 shares issued, respectively		—			—
Common shares, no par value, 71,000,000 shares authorized, 41,714,185 and 41,622,216 shares issued, respectively							—			—
Additional paid-in capital		114,123			111,851		114,840			111,851
Retained earnings		50,169			48,869		50,928			48,869
Accumulated other comprehensive income		(3,194	)		309		(1,837	)		309


Total shareholders’ equity		161,098			161,029		163,931			161,029


TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	178,312		$	176,929	$	179,316		$	176,929

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Unaudited)


	Common Shares Issued		Additional Paid-In Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Shareholders’ Equity			Common Shares Issued		Additional Paid-In Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Shareholders’ Equity

Balance at September 30, 2014		41,622	$	111,851	$	48,869		$	309		$	161,029			41,622	$	111,851	$	48,869		$	309		$	161,029

Cash dividends paid		—		—		(16,671	)		—			(16,671	)		—		—		(25,014	)		—			(25,014	)

Exercise of stock options		65		318		—			—			318			65		313		—			—			313

Conversion of restricted stock units		27		—		—			—			—			27		—		—			—			—

Stock compensation expense		—		1,954		—			—			1,954			—		2,676		—			—			2,676

Net earnings		—		—		17,971			—			17,971			—		—		27,073			—			27,073

Foreign currency translation adjustment		—		—		—			(3,503	)		(3,503	)		—		—		—			(2,146	)		(2,146	)

Balance at June 30, 2015															41,714	$	114,840	$	50,928		$	(1,837	)	$	163,931

Balance at March 31, 2015		41,714	$	114,123	$	50,169		$	(3,194	)	$	161,098

The accompanying notes are an integral part of these condensed consolidated financial statements.

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of ~~March 31,~~June 30, 2015, the results of its operations for the three and ~~six~~nine month periods ended ~~March 31,~~June 30, 2015 and 2014, and its cash flows for the ~~six~~nine month periods ended ~~March 31,~~June 30, 2015 and 2014. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s fiscal 2014 Annual Report on Form 10-K. Financial information as of September 30, 2014 has been derived from the Company’s audited consolidated financial statements.

The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

Revenue is generally recognized from sales when product is shipped and title has passed to the customer. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments due certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, estimates of inventories of certain of our products held by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals were ~~$4,650~~$4,431 at ~~March 31,~~June 30, 2015 and $4,220 at September 30, 2014, and have been netted against accounts receivable.

Revenue for our Diagnostics segment includes revenue for ourillumigene^® molecular test system. This system includes an instrument, instrument accessories and test kits. In markets where the test system is sold via multiple deliverable arrangements, the cost of the instrument and instrument accessories is deferred upon placement at a customer and amortized on a straight-line basis into cost of sales over the expected utilization period, generally three years.

We evaluate whether each deliverable in the arrangement is a separate unit of accounting. The significant deliverables are an instrument, instrument accessories (e.g., printer) and test kits. An instrument and instrument accessories are delivered to the customer prior to the start of the customer utilization period, in order to accommodate customer set-up and installation. There isde minimis consideration received from the customer at the time of instrument placement. We have determined that the instrument and instrument accessories are not a separate unit of accounting because such equipment can only be used to process and read the results from ourillumigene diagnostic tests (i.e., our instrument and test kits function together to deliver a diagnostic test result), and therefore the instrument and instrument accessories do not have standalone value to the customer. Consequently, there is no revenue allocated to the placement of the instrument and instrument accessories. Test kits are delivered to the customer over the utilization period of the instrument, which we estimate has a useful life of three years. Our average customer contract period, including estimated renewals, is at least equal to the estimated three-year utilization period. Revenue for the sale of test kits is recognized upon shipment and transfer of title to the customers.

In markets where the test system is not sold via multiple deliverable arrangements, the cost of the instrument and instrument accessories is charged to cost of sales at the time of shipment and transfer of title to the customer. Revenue for the sales of instruments and instrument accessories and test kits is recognized upon shipment and transfer of title to the customers. In these markets, ourillumigenemolecular test system is sold to independent distributors who inventory the instruments, instrument accessories and test kits for resale to end-users.

Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was considered to be probable and estimable.

Life Science revenue for contract services may come from research and development services or manufacturing services, including process development work, or a combination of both. Revenue is recognized based on each of the deliverables in a given arrangement having distinct and separate customer pricing. Depending on the nature of the arrangement, revenue is recognized as services are performed and billed, upon completion and acceptance by the customer, or upon delivery of product and acceptance by the customer.

Trade accounts receivable are recorded in the accompanying Condensed Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience and known conditions that would likely lead to non-payment. The allowance for doubtful accounts and related metrics, such as days’ sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid.

As reflected in the accompanying Condensed Consolidated Statements of Comprehensive Income, our comprehensive income or loss is comprised of net earnings and foreign currency translation.

Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included as a separate component of comprehensive income or loss. Revenues and expenses are translated using exchange rates prevailing during the period. We also recognize foreign currency transaction gains and losses on certain assets and liabilities that are denominated in the non-functional currencies of the Company or its subsidiaries. These gains and losses are included in other income and expense in the accompanying Condensed Consolidated Statements of Operations.

The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. We prepare estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of our tax returns, typically occurring in the third and fourth quarters of the current fiscal year for the preceding fiscal year’s estimates.

We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being ultimately realized upon settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest and penalties related to unrecognized tax benefits as a portion of our income tax provision in the Condensed Consolidated Statements of Operations.

In September 2013, the Internal Revenue Service issued Treasury Decision 9636, which enacted final tax regulations regarding the capitalization and expensing of amounts paid to acquire, produce or improve tangible property. The regulations also include guidance regarding the retirement of depreciable property. Our adoption of these regulations on October 1, 2014 did not have a significant impact on the Company’s consolidated results of operations, cash flows or financial position.

We recognize compensation expense for all share-based awards made to employees, based upon the fair value of the share-based award on the date of the grant. Awards are expensed over their requisite service periods. For awards which vest solely on future service, we begin to expense such awards on the date of grant. For awards with performance conditions, we begin to expense such awards in the period upon which we believe there is sufficient evidence to support that it is probable that the performance condition(s) will be achieved.


	March 31, 2015				September 30, 2014				June 30, 2015				September 30, 2014
	Cash and Equivalents		Other Assets		Cash and Equivalents		Other Assets		Cash and Equivalents		Other Assets		Cash and Equivalents		Other Assets
Overnight repurchase agreements	$	21,294	$	—	$	26,407	$	—	$	23,315	$	—	$	26,407	$	—

Cash on hand -
Restricted		—		1,000		—		1,000		—		1,000		—		1,000
Unrestricted		21,425		—		16,640		—		22,660		—		16,640		—

Total	$	42,719	$	1,000	$	43,047	$	1,000	$	45,975	$	1,000	$	43,047	$	1,000

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09,Revenue from Contracts with Customers, which supersedes and replaces nearly all currently-existing U.S. GAAP revenue recognition guidance including related disclosure requirements. ~~This~~Considering the FASB’s recent effective date deferral, this guidance will be effective for the Company beginning October 1, ~~2017.~~2018 (fiscal 2019). The Company has not yet completed its assessment of the impact that adoption of this guidance will have on its financial statements.

Certain reclassifications have been made to the prior fiscal period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.


	March 31, 2015		September 30, 2014		June 30, 2015		September 30, 2014
Raw materials	$	7,005	$	5,674	$	6,637	$	5,674
Work-in-process		9,302		10,591		9,189		10,591
Finished goods -*illumi*gene instruments		1,337		1,710		1,277		1,710
Finished goods - kits and reagents		15,399		17,520		16,489		17,520

Total	$	33,043	$	35,495	$	33,592	$	35,495

Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Our reportable segments are Diagnostics and Life Science, both of which are headquartered in Cincinnati, Ohio, which also serves as the Diagnostics segment’s base of manufacturing operations and research and development. The Diagnostics segment has sales and distribution facilities in the United States, Europe and Australia. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents, domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Amounts due from two Diagnostics distributor customers accounted for ~~20%~~23% and 15% of consolidated accounts receivable at ~~March 31,~~June 30, 2015 and September 30, 2014, respectively. Revenues from these two distributor customers accounted for ~~32%~~35% and ~~35%~~36% of the Diagnostics ~~segment~~segment’s third-party revenues during the three months ended ~~March 31,~~June 30, 2015 and 2014, respectively, and 36% during each of the ~~six~~nine months ended ~~March 31,~~June 30, 2015 and 2014. These distributors represented ~~24% and 26%~~27% of consolidated revenues for each of the fiscal 2015 and 2014 third quarters, and 27% and 28% for the fiscal 2015 and 2014 ~~second quarters, respectively, and 27% for each of the respective~~ year-to-date ~~six~~nine month ~~periods.~~periods, respectively. In addition, approximately ~~$2,100~~$2,000 and $2,700 of our consolidated accounts receivable at ~~March 31,~~June 30, 2015 and September 30, 2014, respectively, was due from Italian hospital customers whose funding ultimately comes from the Italian government, representing 7% and 12% of consolidated accounts receivable in each of the respective periods.

Within our Life Science segment, two diagnostic manufacturing customers accounted for 16% ~~and 23%~~ of the segment’s third-party revenues during each of the three months ended ~~March 31,~~June 30, 2015 and 2014, ~~respectively,~~and 16% and 17% during ~~each of~~ the ~~six~~nine months ended ~~March 31,~~June 30, 2015 and ~~2014.~~2014, respectively.


	Diagnostics		Life Science		Eliminations(1)			Total		Diagnostics		Life Science		Eliminations(1)			Total
Three Months Ended March 31, 2015
Three Months Ended June 30, 2015
Net revenues -
Third-party	$	38,662	$	12,883	$	—		$	51,545	$	36,049	$	12,155	$	—		$	48,204
Inter-segment		84		226		(310	)		—		46		345		(391	)		—
Operating income		11,951		3,728		53			15,732		11,203		3,240		(45	)		14,398
Goodwill (March 31, 2015)		1,250		20,840		—			22,090
Other intangible assets, net (March 31, 2015)		2,542		4,049		—			6,591
Total assets (March 31, 2015)		115,470		63,116		(274	)		178,312
Three Months Ended March 31, 2014
Goodwill (June 30, 2015)											1,250		21,534		—			22,784
Other intangible assets, net (June 30, 2015)											2,436		3,938		—			6,374
Total assets (June 30, 2015)											117,602		61,955		(241	)		179,316

Three Months Ended June 30, 2014
Net revenues -
Third-party	$	37,061	$	13,073	$	—		$	50,134	$	35,168	$	12,044	$	—		$	47,212
Inter-segment		154		225		(379	)		—		99		374		(473	)		—
Operating income		12,301		3,306		59			15,666		10,526		2,676		(70	)		13,132
Goodwill (September 30, 2014)		1,250		21,943		—			23,193		1,250		21,943		—			23,193
Other intangible assets, net (September 30, 2014)		2,756		5,057		—			7,813		2,756		5,057		—			7,813
Total assets (September 30, 2014)		109,350		67,834		(255	)		176,929		109,350		67,834		(255	)		176,929

Six Months Ended March 31, 2015
Nine Months Ended June 30, 2015
Net revenues -
Third-party	$	75,248	$	24,310	$	—		$	99,558	$	111,297	$	36,465	$	—		$	147,762
Inter-segment		189		522		(711	)		—		235		867		(1,102	)		—
Operating income		21,878		6,574		(51	)		28,401		33,081		9,814		(96	)		42,799
Six Months Ended March 31, 2014

Nine Months Ended June 30, 2014
Net revenues -
Third-party	$	71,898	$	23,030	$	—		$	94,928	$	107,066	$	35,074	$	—		$	142,140
Inter-segment		263		484		(747	)		—		362		858		(1,220	)		—
Operating income		21,685		5,567		40			27,292		32,211		8,243		(30	)		40,424

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

A summary of our acquired intangible assets subject to amortization, as of ~~March 31,~~June 30, 2015 and September 30, 2014, is as follows:


	March 31, 2015				September 30, 2014				June 30, 2015				September 30, 2014
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization

Manufacturing technologies, core products and cell lines	$	11,550	$	10,677	$	11,685	$	10,568	$	11,635	$	10,849	$	11,685	$	10,568
Trademarks, licenses and patents		6,280		2,969		6,463		2,766		6,390		3,167		6,463		2,766
Customer lists and supply agreements		12,020		9,613		12,378		9,379		12,246		9,881		12,378		9,379

	$	29,850	$	23,259	$	30,526	$	22,713	$	30,271	$	23,897	$	30,526	$	22,713

The actual aggregate amortization expense for these intangible assets was ~~$431~~$409 and ~~$516~~$507 for the three months ended ~~March 31,~~June 30, 2015 and 2014, respectively, and ~~$900~~$1,309 and ~~$1,042~~$1,549 for the ~~six~~nine months ended ~~March 31,~~June 30, 2015 and 2014, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2020 is as follows: remainder of fiscal 2015 – ~~$766,~~$402, fiscal 2016 – ~~$1,326,~~$1,369, fiscal 2017 – ~~$1,110,~~$1,141, fiscal 2018 – ~~$1,090,~~$1,120, fiscal 2019 – ~~$1,049~~$1,079 and fiscal 2020 – ~~$877.~~$903.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Refer to “Forward Looking Statements” following the Table of Contents in front of this Form 10-Q. In the discussion that follows, all dollar amounts are in thousands (both tables and text), except per share data.

Following is a discussion and analysis of the financial statements and other statistical data that management believes will enhance the understanding of Meridian’s financial condition, changes in financial condition and results of operations. This discussion should be read in conjunction with the financial statements and notes thereto beginning on page 1.

As more fully detailed below, the ~~second~~third quarter of fiscal 2015 was highlighted by our Diagnostics segment’s launch of ~~four new products~~our newest molecular-based tests for the detection of Herpes Simplex Virus Type 1 (“HSV-1”) and Type 2 (“HSV-2”) outside of the U.S. and our Life Science segment’s continued successful expansion into China, ~~and launch of five new RNA tests. The Diagnostics products launched during the quarter include tests~~as revenues from sales into China now exceed $1,500 in fiscal 2015 year-to-date. During July 2015, we received FDA clearance for ~~two additional diseases to be performed on~~ ourillumigene^®~~molecular testing platform (~~~~Chlamydia trachomatis~~HSV 1&2 tests and~~Neisseria gonorrhea) and two new immunoassay products to test for~~~~Streptococcus pneumoniae (S. pneumo~~~~) and~~~~H. pylori~~ ~~– TRU STREP PNEUMO~~^TM ~~and Immuno~~~~Card~~ ~~STAT!~~^® HpSA HD, respectively. During the second quarter of fiscal 2015, our Life Science segment’s revenue from sales of immunoassay component products into China increased to approximately $500 compared to less than $50 began selling in the ~~fiscal 2014 second quarter.~~U.S. market.

Net earnings for the ~~second~~third quarter of fiscal 2015 ~~decreased 2%~~increased 3% to ~~$10,070,~~$9,102, or ~~$0.24~~$0.22 per diluted share, from net earnings for the ~~second~~third quarter of fiscal 2014 of ~~$10,300,~~$8,835, or ~~$0.24~~$0.21 per diluted share. This ~~decrease~~increase reflects the combined effects of increased revenues, ~~slightly~~ increased gross profit margins and ~~increased~~slightly decreased operating expenses. Also impacting the quarterly results was an increase in the effective tax rate, as discussed below, which had an approximate $0.01 impact on diluted earnings per share. Consolidated revenues increased 3%2% to ~~$51,545~~$48,204 for the ~~second~~third quarter of fiscal 2015 compared to the same period of the prior year, increasing 6%5% on a constant-currency basis.

Included within the ~~second~~third quarter 2015 results were revenues from ourillumigene^®molecular platform of products totaling ~~$10,192,~~$10,500, representing a 5%10% increase over the fiscal 2014 ~~second~~third quarter. Also contributing to the increase in consolidated revenues were increased revenues in ~~three~~two of our diagnostic focus product families (H. pylori~~, foodborne~~ and respiratory). and our Life Science segment’s immunoassay components business. Serving to partially offset these increases were decreased revenues in ourC. difficile and foodborne focus product ~~family~~families and ~~both of~~ our Life Science segment’s ~~business lines (i.e.,~~ molecular ~~component and immunoassay component).~~components business.

Revenues for the Diagnostics segment for the ~~second~~third quarter of fiscal 2015 increased 4%3% compared to the ~~second~~third quarter of fiscal 2014 ~~(7%~~(5% on a constant-currency basis), reflecting the following for each of our focus product families: ~~7% growth in our respiratory products, 9%~~8% growth in ourH. pylori products, ~~27%~~35% growth in our respiratory products, 2% decline in our foodborne products, and ~~10%~~8% decline in ourC. difficile products. As it relates to our respiratory products, the growth ~~is substantially~~was driven by several products in both our molecular ~~respiratory~~and immunoassay categories. Our molecular products (illumigene Group A Strep,illumigene Mycoplasma andillumigene ~~Pertussis products), which were launched into the market over the past two-plus years~~Pertussis) experienced volume growth from new assay placements. Our immunoassay products (influenza and ~~represent an increasing percentage of our respiratory product family revenues.~~Mycoplasma) experienced growth in distribution channels. With ~~declines~~growth in ~~both~~its immunoassay components business and a decline in its molecular ~~component and immunoassay component~~components business, revenues of our Life Science segment ~~decreased~~increased by 1% during the ~~second~~third quarter of fiscal 2015 compared to the ~~second~~third quarter of fiscal 2014, increasing 1%5% on a constant-currency basis.

For the ~~six~~nine month period ended ~~March 31,~~June 30, 2015, net earnings increased 1%2% to ~~$17,971,~~$27,073, or ~~$0.43~~$0.64 per diluted share, from net earnings for the comparable fiscal 2014 period of ~~$17,726,~~$26,561, or ~~$0.42~~$0.63 per diluted share. This increase reflects the combined effects of increased revenues, slightly decreased gross profit margins and increased operating expenses. Consolidated revenues increased 5%4% to ~~$99,558~~$147,762 for the first ~~six~~nine months of fiscal 2015 compared to the same period of the prior fiscal year, increasing 7%6% on a constant-currency basis.

Included within the ~~six~~nine month year-to-date fiscal 2015 results were revenues from ourillumigene molecular platform of products totaling ~~$20,100,~~$30,600, representing a 10% increase over the first ~~six~~nine months of fiscal 2014. Also contributing to the consolidated ~~revenues~~revenue increase were increased revenues in three of our diagnostic focus product families (H. pylori, foodborne and respiratory) and ~~both of~~ our Life Science segment’s ~~business lines (i.e., molecular component and~~ immunoassay ~~component).~~components business. Serving to partially offset these increases were decreased revenues in ourC. difficile focus product ~~family.~~family and our Life Science segment’s molecular components business.

During the first ~~six~~nine months of fiscal 2015, revenues for the Diagnostics segment increased 5%4% from the comparable fiscal 2014 period ~~(7%~~(6% on a constant-currency basis), reflecting the following for each of our focus product families: 10% growth in ourH. pylori products, ~~16%~~10% growth in our foodborne products, ~~18%~~23% growth in our respiratory products, and ~~11%~~10% decline in ourC. difficile products. ~~As it relates to our respiratory products,~~During the ~~growth is substantially driven by our molecular respiratory products (~~~~illumi~~~~gene~~ ~~Group A Strep,~~~~illumi~~~~gene~~ ~~Mycoplasma and~~~~illumi~~~~gene~~ ~~Pertussis products), which were launched into the market over the past two-plus years and represent an increasing percentage~~first nine months of ~~our respiratory product family revenues. With growth in both its molecular component and immunoassay component business,~~fiscal 2015, revenues offor our Life Science segment increased ~~6% during the six months ended March 31, 2015 over the comparable fiscal 2014 period, increasing 8%~~4%, 7% on a constant-currency basis.

Below are analyses of the Company’s revenue, provided for each of the following:

Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the countries comprising North, Central and South America (the “Americas”); Europe, Middle East and Africa (“EMEA”); and other countries outside of

the Americas and EMEA (rest of the world, or “ROW”). The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents, domestically and abroad, including a sales and business development location in Singapore. Additionally, in order to further pursue growing revenue opportunities in Asia, and China in

particular, our Life Science segment has opened a business development office in Beijing, China. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Revenues for the Diagnostics segment, in the normal course of business, may be affected from quarter to quarter by buying patterns of major distributors, seasonality and strength of certain diseases, and foreign currency exchange rates. Revenues for the Life Science segment, in the normal course of business, may be affected from quarter to quarter by the timing and nature of arrangements for contract services work, which may have longer production cycles than bioresearch reagents and bulk antigens and antibodies, as well as buying patterns of major customers, and foreign currency exchange rates. We believe that the overall breadth of our product lines serves to reduce the variability in consolidated revenues due to these factors.


	Three Months Ended March 31,									Six Months Ended March 31,
	2015			2014			Inc (Dec)			2015			2014			Inc (Dec)			Three Months Ended June 30,									Nine Months Ended June 30,
																			2015			2014			Inc (Dec)			2015			2014			Inc (Dec)
Diagnostics-
Americas	$	32,179		$	30,312			6	%	$	63,092		$	58,573			8	%	$	30,410		$	28,881			5	%	$	93,502		$	87,454			7	%
EMEA		5,530			5,952			(7	)%		10,533			11,325			(7	)%		4,651			5,485			(15	)%		15,184			16,810			(10	)%
ROW		953			797			20	%		1,623			2,000			(19	)%		988			802			23	%		2,611			2,802			(7	)%

Total Diagnostics		38,662			37,061			4	%		75,248			71,898			5	%		36,049			35,168			3	%		111,297			107,066			4	%


Life Science-
Americas		5,910			5,102			16	%		11,209			9,415			19	%		5,065			4,842			5	%		16,274			14,257			14	%
EMEA		5,002			6,199			(19	)%		8,760			10,009			(12	)%		4,877			5,278			(8	)%		13,637			15,287			(11	)%
ROW		1,971			1,772			11	%		4,341			3,606			20	%		2,213			1,924			15	%		6,554			5,530			19	%

Total Life Science		12,883			13,073			(1	)%		24,310			23,030			6	%		12,155			12,044			1	%		36,465			35,074			4	%

Consolidated	$	51,545		$	50,134			3	%	$	99,558		$	94,928			5	%	$	48,204		$	47,212			2	%	$	147,762		$	142,140			4	%


% of total revenues-
Diagnostics		75	%		74	%					76	%		76	%					75	%		74	%					75	%		75	%
Life Science		25	%		26	%					24	%		24	%					25	%		26	%					25	%		25	%

Total		100	%		100	%					100	%		100	%					100	%		100	%					100	%		100	%

Ex-Americas		26	%		29	%					25	%		28	%					26	%		29	%					26	%		28	%

The revenues generated by each of our reportable segments result primarily from the sale of the following segment-specific categories of products:

Revenues for each product platform/type, as well as its relative percentage of segment revenue, are shown below.


	Three Months Ended March 31,									Six Months Ended March 31,									Three Months Ended June 30,									Nine Months Ended June 30,
	2015			2014			Inc (Dec)			2015			2014			Inc (Dec)			2015			2014			Inc (Dec)			2015			2014			Inc (Dec)
Diagnostics-
Molecular	$	10,192		$	9,737			5	%	$	20,100		$	18,287			10	%
Immunoassay		28,470			27,324			4	%		55,148			53,611			3	%
Molecular tests																			$	10,550		$	9,578			10	%	$	30,650		$	27,865			10	%
Immunoassay tests																				25,499			25,590			—	%		80,647			79,201			2	%

Total Diagnostics	$	38,662		$	37,061			4	%	$	75,248		$	71,898			5	%	$	36,049		$	35,168			3	%	$	111,297		$	107,066			4	%


Life Science-
Molecular components	$	4,893		$	5,023			(3	)%	$	9,905		$	9,893			—	%	$	5,104		$	5,476			(7	)%	$	15,009		$	15,369			(2	)%
Immunoassay components		7,990			8,050			(1	)%		14,405			13,137			10	%		7,051			6,568			7	%		21,456			19,705			9	%

Total Life Science	$	12,883		$	13,073			(1	)%	$	24,310		$	23,030			6	%	$	12,155		$	12,044			1	%	$	36,465		$	35,074			4	%


% of Diagnostics revenues-
Molecular		26	%		26	%					27	%		25	%
Immunoassay		74	%		74	%					73	%		75	%
Molecular tests																				29	%		27	%					28	%		26	%
Immunoassay tests																				71	%		73	%					72	%		74	%

Total Diagnostics		100	%		100	%					100	%		100	%					100	%		100	%					100	%		100	%


% of Life Science revenues-
Molecular components		38	%		38	%					41	%		43	%					42	%		45	%					41	%		44	%
Immunoassay components		62	%		62	%					59	%		57	%					58	%		55	%					59	%		56	%

Total Life Science		100	%		100	%					100	%		100	%					100	%		100	%					100	%		100	%

Following is a discussion of the revenues generated by each of these product platforms/types:

Following our launch outside the U.S. ofillumigene^®HSV 1&2 during the third quarter of fiscal 2015 andillumigene Chlamydia trachomatis andillumigene^®Neisseria gonorrhea during the second quarter of fiscal 2015, we now have ~~just over 1,400~~approximately 1,425 customer account placements. Of these account placements, approximately ~~1,240~~1,275 accounts have completed evaluations and validations and are regularly purchasing product, with the balance of our account placements being in some stage of product evaluation and/or validation. Of our account placements, we have approximately 400 accounts that are regularly purchasing, evaluating and/or validating two or more assays.

We continue to invest in new product development for our molecular testing platform,illumigene. This platform now has ~~seven~~the following commercialized ~~tests, with one additional test expected to be available for sale in fiscal 2015:~~tests:

Additionalillumigene tests in ~~early-stage~~ research and development include foodborne pathogens such asCampylobacter jejuni, and bloodborne pathogens such as the causative agents for malaria.

We believe that the diagnostic testing market is continuing to selectively move away from culture and immunoassay testing to molecular testing for diseases where there is a favorable cost/benefit position for the total cost of health care. While this market is competitive, with molecular companies such as Cepheid and Becton Dickinson and ~~more recent entrants~~others such as Quidel, Great Basin, Nanosphere, and ~~others,~~Alere, we believe we are well positioned to capitalize on the migration to molecular testing. Our simple, easy-to-use,illumigene platform, with its expanding menu, requires no expensive equipment purchase and little to no maintenance cost. We believe these features, along with its small footprint and the performance of theillumigene assays, makeillumigene an attractive molecular platform to any size hospital or physician office laboratory that runs moderately-complex tests.

~~Having launched our TRU STREP PNEUMO~~^TM ~~and Immuno~~~~Card~~ ~~STAT!~~^® ~~HpSA HD products outside the U.S. during the second quarter of fiscal 2015, our~~Our Diagnostics segment’s revenues from immunoassay products ~~increased 4%~~decreased less than 1% for the quarter and increased 3%2% on a ~~six~~nine month, year-to-date basis. As described in the product discussions below, the quarterly revenue growth of ourH. pyloriand respiratory products was slightly more than offset by the decline in revenues from our foodborne andC. difficile products. The year-to-date ~~increases both result~~increase results primarily from the revenue growth of ourH. pylori, foodborne and respiratory products, partially offset by the decline in revenues from ourC. difficile products.

During the ~~second~~third quarter of fiscal 2015, revenues from our Life Science segment ~~decreased~~increased 1%, with revenues from molecular ~~component~~components sales decreasing 3%7% from the comparable fiscal 2014 quarter and revenues from immunoassay ~~component~~components sales ~~decreasing 1%~~increasing 7%. For the first ~~six~~nine months of fiscal 2015, revenues from our Life Science segment increased 6%4%, with revenues from molecular ~~component~~components sales ~~increasing less than 1% over~~decreasing 2% from the comparable prior year period and revenues from immunoassay ~~component~~components sales increasing ~~10%~~9%. Our molecular ~~component~~components business’ growth was negatively impacted by the movement in currency exchange rates since the 2014 ~~second~~third quarter, with revenues increasing 5%2% and 6%4% on a constant-currency basis for the quarterly and year-to-date periods, respectively. ~~The revenue level of our immunoassay component business faced a difficult prior year comparison (i.e., in fiscal 2014, certain shipments were delayed and shifted~~Our Life Science segment continued to benefit from ~~the first quarter to the second quarter). The effects of the timing of these prior year shipments were partially offset by the~~increased sales into China, ofwith such sales totaling approximately ~~$500~~$1,600 for the ~~quarter~~first nine months of fiscal 2015 (approximately ~~$1,100 for~~$400 in the ~~year-to-date period)~~molecular components business and $1,200 in the immunoassay components business).

Revenues from our focus families (C. difficile, foodborne,H. pylori, and respiratory) comprised 74% of our Diagnostics segment’s revenue during the ~~second~~third quarter and first ~~six~~nine months of fiscal 2015, and 73% for both of the comparable fiscal 2014 periods. Following is a discussion of the revenues generated by each product family:

Revenues for ourC. difficile product family decreased ~~10%~~8% to $8,200 for the fiscal 2015 ~~second~~third quarter, and decreased ~~11%~~10% to ~~$15,800~~$24,000 for the ~~six~~nine month, year-to-date period. ~~This decrease reflects the combined effects of revenue from new~~~~illumi~~~~gene~~ ~~customers, the loss of several larger~~~~illumi~~~~gene~~~~customers in fiscal 2014 and reduced revenues from our immunoassay~~Our molecular products ~~which~~ now represent ~~less than 25%~~approximately 80% of this product ~~category.~~category, and new customers are being added each quarter. TheC. difficile test market continues to be highly competitive, with over 10 suppliers in the United States, certain of which choose to compete solely on

price. We believe that the following factors will help us respond to these ~~challenging~~highly competitive market conditions: (i) our marketing programs emphasize that we are the only company that can offer a full range of high performing, FDA cleared,C. difficile testing formats, including toxin, GDH and molecular tests; (ii) ourillumigene molecular platform, with its expanding differentiated menu, affords both an opportunity to grow the platform utilization within the hospital, as well as protect against competitive threats; and (iii) ourillumigene molecular platform requires no expensive equipment purchase or maintenance contract, which we believe makes it an attractive and affordable option for any size hospital.

Revenues for our foodborne products (EnterohemorrhagicE. coli(“EHEC”) andCampylobacter), all of which are immunoassay products, totaled ~~$6,900~~$5,700 during the fiscal 2015 ~~second~~third quarter, a ~~27% increase~~2% decrease from the fiscal 2014 ~~second~~third quarter. During the ~~six~~nine months ended ~~March 31,~~June 30, 2015, foodborne revenues totaled ~~$12,800,~~$18,500, a ~~16%~~10% increase from the fiscal 2014 year-to-date period. ~~These~~Revenues for our foodborne products on a quarterly basis (up 5% in the first quarter, up 27% in the second quarter and ~~year-to-date increases reflect~~down 2% in the ~~positive effects of a large~~third quarter) have been affected by distributor ~~order made in connection with~~ordering patterns and our inside and field sales programs designed to protect and expand upon our current customer base through the addition of new customers adopting rapid tests and competitive

takeaways. ~~Excluding the effects of this order, fiscal 2015 second quarter and first six month revenues increased 17% and 11%, respectively, over the comparable fiscal 2014 periods.~~ We are continuing to re-emphasize the benefits of increased sensitivity and faster turnaround time versus culture methods in our marketing programs. The primary competition for our foodborne products is laboratory culture methods and an immunoassay shiga toxin test from one of our competitors. We believe that our test offers better workflow, less hands-on time and quicker results, in addition to being fully compliant with CDC-recommended testing methods.

During the ~~second~~third quarter of fiscal 2015, revenues from ourH. pylori products, all of which are immunoassay products, grew 9%8% to ~~$7,700.~~$8,000. These revenues grew 10% to ~~$15,000~~$23,000 during the first ~~six~~nine months of fiscal 2015. These increases continue to reflect the benefits of our partnerships with managed care companies in promoting (i) the health and economic benefits of a test and treat strategy; (ii) changes in policies that discourage the use of traditional serology methods and promote the utilization of active infection testing methods; and (iii) ~~moving~~ physician behavior movement away from serology-based testing and toward direct antigen testing. A significant amount of theH. pylori product revenues are to reference labs, whose buying patterns may not be consistent period to period.

The patents for ourH. pylori products are owned by us and expire in 2016 in the U.S. and in 2017 in countries outside the U.S. We expect competition with respect to ourH. pylori products to increase upon the expiration of these patents in 2016 and 2017 as we currently market the only FDA-cleared test to detectH. pylori antigen in stool samples. Such competition may have an adverse impact on our selling prices for these products, or our ability to retain business at prices acceptable to us, and consequently, adversely affect our future results of operations and liquidity, including revenues and gross profit. In order to mitigate any loss in revenues upon patent expiration, among other things, we are researching and experimenting with new products (e.g., detection ofH. pylori in samples other than stool and detection ofH. pylori on molecular platforms). We are unable to provide any assurances that we will be successful with any mitigation strategy or that any mitigation strategy will prevent an adverse effect on our future results of operations and liquidity, including revenues and gross profit.

Total respiratory revenues from our Diagnostics segment increased 7%35% to ~~$5,800~~$5,000 during the fiscal 2015 ~~second~~third quarter; and increased ~~18%~~23% to ~~$12,000~~$17,000 for the ~~six~~nine month year-to-date period. Growth was driven by several products in both our molecular and immunoassay categories. Our molecular ~~respiratory~~ products (illumigene Group A Strep,illumigene Mycoplasma andillumigene ~~Pertussis products), which were launched into~~ Pertussis) experienced volume growth from new assay placements. Our immunoassay products (influenza and Mycoplasma) experienced growth as a result of increases in Japanese orders of our Mycoplasma product and a large purchase by a distributor of influenza product in advance of the market over the past two-plus years, experienced 94% and 149% growth during the second quarter of fiscal 2015 and the six months ended March 31, 2015, respectively. Serving to partially offset these increases were declines in our immunoassay respiratory products of 15% and 11% for the quarterly and six month year-to-date periods, respectively, reflecting both the decline in revenues from sales of such products in Japan due to continuing issues related to our Japanese distributor having been acquired last year and lower influenza ~~sales.~~season.

During the ~~second~~third quarter of fiscal 2015, currency exchange rates had a ~~$1,400~~$1,500 unfavorable impact on revenue; $1,000 unfavorable within the Diagnostics segment and ~~$400~~$500 unfavorable within the Life Science segment. On a ~~six~~nine month year-to-date basis, currency exchange rates had a ~~$2,000~~$3,500 unfavorable impact on revenue; ~~$1,400~~$2,500 unfavorable within the Diagnostics segment and ~~$600~~$1,000 unfavorable within the Life Science segment.

Two U.S. distributors accounted for ~~32%~~35% and ~~35%~~36% of our Diagnostics segment’s total revenues for the ~~second~~third quarter of fiscal 2015 and 2014, respectively, and 36% during each of the ~~six~~nine months ended ~~March 31,~~June 30, 2015 and 2014. These distributors represented 27% of consolidated revenues for each of the fiscal 2015 and 2014 ~~respectively. These distributors represented 24%~~third quarters, and ~~26% of consolidated revenues~~27% and 28% for the fiscal 2015 and 2014 ~~second quarters, respectively, and 27% for each of the respective~~ year-to-date ~~six~~nine month ~~periods.~~periods, respectively.

Within our Life Science segment, two diagnostic manufacturing customers accounted for 16% ~~and 23%~~ of the segment’s total revenues for each of the ~~second quarter~~third quarters of fiscal 2015 and 2014, ~~respectively,~~and 16% and 17% during ~~each of~~ the ~~six~~nine months ended ~~March 31,~~June 30, 2015 and 2014, respectively.


	Three Months Ended March 31,									Six Months Ended March 31,									Three Months Ended June 30,									Nine Months Ended June 30,
	2015			2014			Change			2015			2014			Change			2015			2014			Change			2015			2014			Change
Gross Profit	$	32,521		$	31,593			3	%	$	61,758		$	59,600			4	%	$	30,331		$	29,242			4	%	$	92,089		$	88,842			4	%

Gross Profit Margin		63	%		63	%		None			62	%		63	%		-1 point			63	%		62	%		+1 point			62	%		63	%		-1 point

Our overall operations consist of the sale of diagnostic test kits for various disease states and in alternative test formats, as well as bioresearch reagents, bulk antigens and antibodies, PCR/qPCR reagents, nucleotides, competent cells, proficiency panels, and contract research and development, and contract manufacturing services. Product revenue mix shifts, in the normal course of business, can cause the consolidated gross profit margin to fluctuate by several points.

Due to our growingillumigene platform, we have invested approximately $4,000 in new molecular manufacturing facilities, which will provide additional manufacturing capacity, as well as improved manufacturing efficiency and quality. We believe that we will begin to realize these efficiencies late in fiscal 2015.


	Six Months Ended March 31, 2015												Three Months Ended June 30, 2015
	Research & Development			Selling & Marketing			General & Administrative			Total Operating Expenses			Research & Development			Selling & Marketing			General & Administrative			Total Operating Expenses
2014 Expenses	$	6,039		$	12,538		$	13,731		$	32,308		$	3,146		$	6,249		$	6,715		$	16,110

% of Revenues		6	%		13	%		14	%		34	%		7	%		13	%		14	%		34	%

Fiscal 2015 Increases (Decreases):
Diagnostics		185			298			889			1,372			20			(55	)		(136	)		(171	)
Life Science		247			(275	)		(295	)		(323	)		48			(10	)		(44	)		(6	)

2015 Expenses	$	6,471		$	12,561		$	14,325		$	33,357		$	3,214		$	6,184		$	6,535		$	15,933

% of Revenues		6	%		13	%		14	%		34	%		7	%		13	%		14	%		33	%
% Increase (Decrease)		7	%		—	%		4	%		3	%		2	%		(1	)%		(3	)%		(1	)%

Overall, total operating expenses decreased during the third quarter of fiscal 2015 and increased during ~~both~~ the ~~second quarter and~~ first ~~six~~nine months of fiscal 2015 relative to the comparable prior fiscal year periods, ~~increasing~~decreasing slightly as a percentage of both quarterly ~~consolidated revenues~~ and ~~remaining relatively flat as a percentage of~~ year-to-date consolidated revenues. These levels of operating expenses result in large part from the combined effects of our (i) ongoing efforts to control spending in each of our segments while investing the necessary resources in our strategic areas of growth, including increased investment in ~~Research & Development for~~new product development in both of our ~~molecular platform products~~segments, and increased investment isin Sales and Marketing personnel and ~~programs;~~programs, particularly in our Diagnostics segment; and (ii) ~~overall increased compensation-related expenses; and (iii)~~ favorable effects of currency rates.

Operating expenses for the Diagnostics segment ~~increased $1,056~~decreased $171 for the ~~second~~third quarter of fiscal 2015 compared to the fiscal 2014 ~~second~~third quarter, and in the first ~~six~~nine months of fiscal 2015, increased ~~$1,372~~$1,201 over the comparable prior year period. These overall Diagnostics segment increases result largely from the combined effects of the following:

Overall increase in spending on new product development activities ~~(during the six month period),~~ related primarily to the previously noted products for ourillumigene molecular platform, as well as immunoassay products in development.

~~Increased~~Increase in year-to-date personnel costs resulting from increased Sales and Marketing ~~headcount, and increased sales commission expenses on increased revenues.~~headcount.

~~An increase~~Increase in profit sharing expense ~~as a result of~~resulting from the previously noted increases in operating profits, ~~partially offset by a decrease~~along with an increase in ~~stock-based compensation resulting in large part from the decline in our stock price relative to the fiscal 2014 periods. In addition to these compensation-related factors,~~ legal spending ~~increased~~ over the prior year related largely to a foreign distributor matter.

Operating income increased ~~less than 1%~~10% to ~~$15,732~~$14,398 for the ~~second~~third quarter of fiscal 2015, and increased 4%6% to ~~$28,401~~$42,799 for the first ~~six~~nine months of fiscal 2015, as a result of the factors discussed above.

The effective rate for income taxes ~~remained stable at 35%~~was 36% and 31% for ~~both~~ the ~~second quarter and first six months~~third quarters of fiscal 2015 ~~increasing slightly~~and 2014, respectively, and 35% and 33% for the nine month year-to-date periods ended June 30, 2015 and 2014, respectively. The higher current year rates relative to fiscal 2014 primarily result from the ~~34% effective rate~~effects of increased tax apportionments in ~~each~~certain state taxing jurisdictions, as well as the prior year period reflecting the positive effects of a net U.S. foreign tax credit resulting from a restructuring of our legal entities during the ~~comparable~~ fiscal 2014 ~~periods.~~third quarter. For the fiscal year ending September 30, 2015, we expect the effective tax rate to approximate ~~34%-35%~~35%.

Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets, consideration of acquisition plans, and consideration of common share dividends. We have historically maintained a credit facility to augment working capital requirements and to respond quickly to acquisition opportunities. Our investment portfolio presently consists of overnight repurchase agreements.

We have an investment policy that guides the holdings of our investment portfolio. Our objectives in managing the investment portfolio are to (i) preserve capital; (ii) provide sufficient liquidity to meet working capital requirements and fund strategic objectives such as acquisitions; and (iii) capture a market rate of return commensurate with market conditions and our policy’s investment eligibility criteria. As we look forward, we will continue to manage the holdings of our investment portfolio with preservation of capital being the primary objective.

We do not expect current conditions in the financial markets, or overall economic conditions, to have a significant impact on our liquidity needs, financial condition, or results of operations, although no assurances can be made in this regard. We intend to continue to fund our working capital requirements and dividends from current cash flows from operating activities and cash on hand. If needed, we also have an additional source of liquidity through our $30,000 bank credit facility, which has been renewed through April 21, 2018. Approximately ~~$2,100~~$2,000 of our consolidated accounts receivable at ~~March 31,~~June 30, 2015 is due from Italian hospital customers whose funding ultimately comes from the Italian government, which is down from approximately $2,700 at September 30, 2014. The amount of our annual revenues in the country of Greece and the corresponding amount of customer receivables outstanding at any point in time is not significant, and therefore, we do not expect any meaningful impact from the current financial crisis in the country of Greece. Our liquidity needs may change if overall economic conditions worsen and/or liquidity and credit within the financial markets tightens for an extended period of time, and such conditions impact the collectibility of our customer accounts receivable, or impact credit terms with our vendors, or disrupt the supply of raw materials and services.

Net cash provided by operating activities totaled ~~$20,031~~$31,196 for the first ~~six~~nine months of fiscal 2015, a ~~48%~~32% increase over the ~~$13,556~~$23,611 provided during the first ~~six~~nine months of fiscal 2014. While reflecting the effects of the timing of federal income tax payments, and the timing of payments from and to customers and suppliers, respectively, this ~~$6,475~~$7,585 increase ~~primarily~~ results in large part from approximately $5,500 of incentive bonus payments related to fiscal 2013 being made in the first quarter of fiscal 2014, with no such payments having been made during the fiscal 2015 year-to-date period. Net cash flows from operating activities and cash on hand are anticipated to be adequate to fund working capital requirements, capital expenditures and dividends during the next 12 months.

We have a $30,000 credit facility with a commercial bank that expires on April 21, 2018. As of ~~April 30,~~July 31, 2015, there were no borrowings outstanding on this facility and we had 100% borrowing capacity available to us. We ~~have~~ had no borrowings outstanding under this facility during the first ~~six~~nine months of fiscal 2015 or during the full year of fiscal 2014.

Our capital expenditures are estimated to be approximately $4,000 for fiscal 2015, with the actual amount depending upon actual operating results and the phasing of certain projects. Such expenditures may be funded with cash and equivalents on hand, operating cash flows, and/or availability under the $30,000 credit facility discussed above.

During June 2015, we sold the land and building related to our former Life Science facility in Saco, Maine. Net proceeds from the sale were approximately $1,138.

We do not utilize any special-purpose financing vehicles or have any undisclosed off-balance sheet arrangements.

There have been no material changes in the Company’s exposure to market risk since September 30, 2014.

As of ~~March 31,~~June 30, 2015, an evaluation was completed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) and 15d-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective as of ~~March 31,~~June 30, 2015. There have been no changes in our internal control over financial reporting identified in connection with the evaluation of internal control that occurred during the ~~second~~third fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, or in other factors that could materially affect internal control subsequent to ~~March 31,~~June 30, 2015.

There have been no material changes from risk factors ~~that could affect the Company’s results of operations, financial condition and liquidity is being expanded~~as previously disclosed in the ~~risk factors discussion provided under~~Registrant’s Form 10-K in response to Item 1A to Part I of Form 10-K as updated by the Registrant’s Form 10-Q for the Quarterly Period ended March 31, 2015 in Item 1A to Part II of ~~the Company’s Annual Report on~~ Form ~~10-K for the fiscal year ended September 30, 2014:~~10-Q.

~~We may face increased competition upon expiration of our~~~~H. pylori~~~~patents in 2016 and 2017.~~

~~Our patents related to our~~~~H. pylori~~ ~~products expire in 2016 in the U.S. and in 2017 in countries outside the U.S. Revenues from our~~~~H. pylori~~ ~~products were $15,000 during the first six months of fiscal 2015. We expect competition with respect to our~~~~H. pylori~~ ~~products to increase upon the expiration of these patents in 2016 and 2017 as we currently market the only FDA-cleared test to detect~~~~H. pylori~~ antigen in stool samples. Such competition may have an adverse impact on our selling prices for these products or our ability to retain business at prices acceptable to us, and consequently, adversely affect our future results of operations and liquidity, including revenues and gross profit. In order to mitigate any loss in revenues upon patent expiration, among other things, we are researching and experimenting with new products (e.g., detection of~~H. pylori~~ ~~in samples other than stool and detection of~~~~H. pylori~~ on molecular platforms). We are unable to provide any assurances that we will be successful with any mitigation strategy or that any mitigation strategy will prevent an adverse effect on our future results of operations and liquidity, including revenues and gross profit.

The following exhibits are being filed or furnished as a part of this Quarterly Report on Form 10-Q.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Class		Outstanding ~~April 30,~~July 31, 2015
Common Stock, no par value		~~41,713,985~~41,714,635


		Page(s)

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Statements of Operations Three and ~~Six~~Nine Months Ended ~~March 31,~~June 30, 2015 and 2014		1

	Condensed Consolidated Statements of Comprehensive Income Three and ~~Six~~Nine Months Ended ~~March 31,~~June 30, 2015 and 2014		2

	Condensed Consolidated Statements of Cash Flows ~~Six~~Nine Months Ended ~~March 31,~~June 30, 2015 and 2014		3

	Condensed Consolidated Balance Sheets ~~March 31,~~June 30, 2015 and September 30, 2014		4-5

	Condensed Consolidated Statement of Changes in Shareholders’ Equity ~~Six~~Nine Months Ended ~~March 31,~~June 30, 2015		6

	Notes to Condensed Consolidated Financial Statements		7-12

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		12-20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		2021

Item 4.	Controls and Procedures		2021

PART II.	OTHER INFORMATION

Item 1A.	Risk Factors		21

Item 6.	Exhibits		2122

Signature			2223


10.1		Amended and Restated Revolving Note with Fifth Third Bank dated April 21, 2015

10.2		Fifth Amendment to Loan and Security Agreement among Meridian Bioscience, Inc., Meridian Bioscience Corporation, Omega Technologies, Inc., Meridian Life Science, Inc., Bioline USA, Inc., and Fifth Third Bank dated April 21, 2015

31.1		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)

31.2		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)

32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101		The following financial information from Meridian Bioscience Inc.’s Quarterly Report on Form 10-Q for the quarter ended ~~March 31,~~June 30, 2015 filed with the SEC on ~~May 11,~~August 10, 2015, formatted in XBRL includes: (i) Condensed Consolidated Statements of Operations for the three and ~~six~~nine months ended ~~March 31,~~June 30, 2015 and 2014; (ii) Condensed Consolidated Statements of Comprehensive Income for the three and ~~six~~nine months ended ~~March 31,~~June 30, 2015 and 2014; (iii) Condensed Consolidated Statements of Cash Flows for the ~~six~~nine months ended ~~March 31,~~June 30, 2015 and 2014; (iv) Condensed Consolidated Balance Sheets as of ~~March 31,~~June 30, 2015 and September 30, 2014; (v) Condensed Consolidated Statement of Shareholders’ Equity for the ~~six~~nine months ended ~~March 31,~~June 30, 2015; and (vi) the Notes to Condensed Consolidated Financial Statements


			MERIDIAN BIOSCIENCE, INC.

Date:	~~May 11,~~August 10, 2015	By:	/s/ Melissa A. Lueke
			Melissa A. Lueke
			Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company